MX2010008198A - Inhibidores de cinasa de pirrolopirazina. - Google Patents
Inhibidores de cinasa de pirrolopirazina.Info
- Publication number
- MX2010008198A MX2010008198A MX2010008198A MX2010008198A MX2010008198A MX 2010008198 A MX2010008198 A MX 2010008198A MX 2010008198 A MX2010008198 A MX 2010008198A MX 2010008198 A MX2010008198 A MX 2010008198A MX 2010008198 A MX2010008198 A MX 2010008198A
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- pyrrolopyrazine
- pyrrolopyrazine kinase
- syk
- immune
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
La presente invención se refiere al uso de nuevos derivados de pirrolopirazina de la fórmula I, (ver fórmula (I)) en la que las variables Q y R tienen los significados aquí definidos, que inhiben la JAK y la SYK y son útiles para el tratamiento de enfermedades autoinmunitarias e inflamatorias.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3103508P | 2008-02-25 | 2008-02-25 | |
US20572409P | 2009-01-22 | 2009-01-22 | |
PCT/EP2009/051757 WO2009106442A1 (en) | 2008-02-25 | 2009-02-16 | Pyrrolopyrazine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2010008198A true MX2010008198A (es) | 2010-08-23 |
Family
ID=40514094
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2010008198A MX2010008198A (es) | 2008-02-25 | 2009-02-16 | Inhibidores de cinasa de pirrolopirazina. |
Country Status (20)
Country | Link |
---|---|
US (1) | US7939531B2 (es) |
EP (1) | EP2247592B1 (es) |
JP (1) | JP5368485B2 (es) |
KR (1) | KR101261514B1 (es) |
CN (1) | CN101939324B (es) |
AR (1) | AR070468A1 (es) |
AT (1) | ATE522535T1 (es) |
AU (1) | AU2009218607B2 (es) |
BR (1) | BRPI0908494A2 (es) |
CA (1) | CA2713710A1 (es) |
CL (1) | CL2009000406A1 (es) |
DK (1) | DK2247592T3 (es) |
IL (1) | IL206358A0 (es) |
MX (1) | MX2010008198A (es) |
PE (1) | PE20091493A1 (es) |
PL (1) | PL2247592T3 (es) |
PT (1) | PT2247592E (es) |
RU (1) | RU2503676C2 (es) |
TW (1) | TWI380987B (es) |
WO (1) | WO2009106442A1 (es) |
Families Citing this family (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009106445A1 (en) * | 2008-02-25 | 2009-09-03 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine kinase inhibitors |
EP2245033B1 (en) * | 2008-02-25 | 2011-08-31 | F. Hoffmann-La Roche AG | Pyrrolopyrazine kinase inhibitors |
ATE522536T1 (de) * | 2008-02-25 | 2011-09-15 | Hoffmann La Roche | Pyrrolopyrazin-kinasehemmer |
CN101952296B (zh) * | 2008-02-25 | 2013-08-21 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
PE20140407A1 (es) | 2008-06-10 | 2014-04-25 | Abbott Lab | Nuevos compuestos triciclicos |
JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
AU2009324894B2 (en) | 2008-11-25 | 2015-04-09 | University Of Rochester | MLK inhibitors and methods of use |
SI3354650T1 (sl) * | 2008-12-19 | 2022-06-30 | Vertex Pharmaceuticals Incorporated | Spojine, uporabne kot zaviralci ATR kinaze |
RS57869B1 (sr) | 2009-06-17 | 2018-12-31 | Vertex Pharma | Inhibitori replikacije virusa gripa |
JP5658756B2 (ja) * | 2009-09-10 | 2015-01-28 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Jakの阻害剤 |
PE20130005A1 (es) | 2009-12-01 | 2013-02-16 | Abbvie Inc | Compuestos triciclicos novedosos |
TW201802091A (zh) | 2009-12-01 | 2018-01-16 | 艾伯維有限公司 | 新穎三環化合物 |
EP2338888A1 (en) * | 2009-12-24 | 2011-06-29 | Almirall, S.A. | Imidazopyridine derivatives as JAK inhibitors |
AU2011210765A1 (en) | 2010-01-28 | 2012-09-13 | President And Fellows Of Harvard College | Compositions and methods for enhancing proteasome activity |
UY33213A (es) | 2010-02-18 | 2011-09-30 | Almirall Sa | Derivados de pirazol como inhibidores de jak |
US8518945B2 (en) | 2010-03-22 | 2013-08-27 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
US8481541B2 (en) * | 2010-03-22 | 2013-07-09 | Hoffmann-La Roche Inc. | Pyrrolopyrazine kinase inhibitors |
RU2012153675A (ru) | 2010-05-12 | 2014-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные в качестве ингибиторов atr киназы |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2569286B1 (en) | 2010-05-12 | 2014-08-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
CN102947272A (zh) | 2010-05-12 | 2013-02-27 | 沃泰克斯药物股份有限公司 | 用作atr激酶抑制剂的2-氨基吡啶衍生物 |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
BR112012029437A2 (pt) * | 2010-05-20 | 2017-03-07 | F Hoffmann - La Roche Ag | derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk |
MX2012013194A (es) | 2010-05-20 | 2013-01-22 | Hoffmann La Roche | Derivados pirrolopirazinas como inhibidores de cinasas tirocina-cinasa del baso (syk) y cinasa de janus (jak). |
CA2800176C (en) * | 2010-05-24 | 2018-08-28 | University Of Rochester | Bicyclic heteroaryl kinase inhibitors and methods of use |
WO2011163527A1 (en) | 2010-06-23 | 2011-12-29 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
WO2012138938A1 (en) | 2011-04-05 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
CN103635230B (zh) | 2011-05-12 | 2017-10-31 | 普罗蒂斯特斯治疗公司 | 蛋白内稳态调节剂 |
EP2710006A1 (en) * | 2011-05-17 | 2014-03-26 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
JP2014522818A (ja) | 2011-06-22 | 2014-09-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
CA2839937C (en) * | 2011-07-05 | 2020-11-03 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing azaindoles |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
CN104024258B (zh) * | 2011-09-01 | 2017-02-15 | 霍夫曼-拉罗奇有限公司 | 吡咯并吡嗪激酶抑制剂 |
MX359032B (es) | 2011-09-01 | 2018-09-12 | Hoffmann La Roche | Inhibidores de pirrolopirazina cinasa. |
JP2014528419A (ja) | 2011-09-30 | 2014-10-27 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼ阻害剤として有用な化合物 |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
CN108685922A (zh) | 2011-09-30 | 2018-10-23 | 沃泰克斯药物股份有限公司 | 用atr抑制剂治疗胰腺癌和非小细胞肺癌 |
IN2014KN00929A (es) | 2011-09-30 | 2015-08-21 | Vertex Pharma | |
BR112014008126A2 (pt) | 2011-11-01 | 2017-04-18 | Hoffmann La Roche | composto, método para o tratamento, composição farmacêutica, utilização de um composto e invenção |
EP2776421A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
EP2776420A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
JP2015502925A (ja) | 2011-11-09 | 2015-01-29 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用なピラジン化合物 |
WO2013071094A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP6109192B2 (ja) | 2012-01-10 | 2017-04-05 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ピリダジンアミド化合物及びsyk阻害剤としてのそれらの使用 |
PL2833973T3 (pl) | 2012-04-05 | 2018-02-28 | Vertex Pharmaceuticals Incorporated | Związki użyteczne jako inhibitory kinazy ATR i ich terapie skojarzone |
BR112015002262A2 (pt) * | 2012-08-21 | 2019-12-10 | Hoffmann La Roche | compostos, métodos para os tratamentos de uma condição inflamatória, artrite reumatóide, asma e distúrbio imunológico; composição farmacêutica, utilização do composto e invenção |
ES2731833T3 (es) | 2012-09-10 | 2019-11-19 | Principia Biopharma Inc | Compuestos pirazolopirimidínicos comos inhibidores de cinasas |
DK2904406T3 (en) | 2012-10-04 | 2018-06-18 | Vertex Pharma | METHOD OF DETERMINING THE ATR INHIBITION, INCREASED DNA DAMAGE |
WO2014062604A1 (en) | 2012-10-16 | 2014-04-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP2016500076A (ja) | 2012-11-20 | 2016-01-07 | プリンシピア バイオファーマ インコーポレイテッド | Jak3阻害剤としてのアザインドール誘導体 |
WO2014085795A1 (en) | 2012-11-30 | 2014-06-05 | University Of Rochester | Mixed lineage kinase inhibitors for hiv/aids therapies |
ES2842876T3 (es) | 2012-12-07 | 2021-07-15 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas útiles como inhibidores de ATR quinasa para el tratamiento de enfermedades de cáncer |
WO2014116228A1 (en) | 2013-01-25 | 2014-07-31 | President And Fellows Of Harvard College | Usp14 inhibitors for treating or preventing viral infections |
JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
CN105209435B (zh) * | 2013-05-14 | 2018-02-02 | 3M创新有限公司 | 包含吡啶或吡嗪的化合物 |
US9296727B2 (en) | 2013-10-07 | 2016-03-29 | Vertex Pharmaceuticals Incorporated | Methods of regioselective synthesis of 2,4-disubstituted pyrimidines |
WO2015073528A1 (en) | 2013-11-12 | 2015-05-21 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
SI3068782T1 (sl) | 2013-11-13 | 2018-10-30 | Vertex Pharmaceuticals Incorporated | Postopki za pripravo inhibitorjev v replikacije virusov gripe |
WO2015080981A1 (en) | 2013-11-27 | 2015-06-04 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
CN103665803B (zh) * | 2013-12-05 | 2015-07-01 | 湖南大学 | 一种基于金属环钯化合物的结晶聚乳酸及其制备方法和金属环钯化合物的应用 |
DK3077397T3 (da) | 2013-12-06 | 2019-12-16 | Vertex Pharma | 2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf |
SG11201606858RA (en) | 2014-02-21 | 2016-09-29 | Principia Biopharma Inc | Salts and solid form of a btk inhibitor |
BR112016028273B1 (pt) | 2014-06-05 | 2022-06-28 | Vertex Pharmaceuticals Incorporated | Composto de fórmula i-a, forma sólida de um composto de fórmula i-1 e seu processo de preparação |
DK3157566T3 (da) | 2014-06-17 | 2019-07-22 | Vertex Pharma | Fremgangsmåde til behandling af cancer under anvendelse af en kombination chk1- og atr-inhibitorer |
DK3164394T3 (da) | 2014-07-03 | 2020-05-04 | Univ Texas | Gls1-inhibitorer til behandling af sygdomme |
WO2016004413A2 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
MA41197B1 (fr) | 2014-12-18 | 2021-01-29 | Principia Biopharma Inc | Traitement de le pemphigus |
EP3288943B1 (en) | 2015-05-01 | 2022-09-28 | Pfizer Inc. | Pyrrolo[2,3-b]pyrazinyl acrylamides and epoxides thereof as inhibitors of janus kinase |
JP6857617B2 (ja) | 2015-05-13 | 2021-04-14 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | インフルエンザウイルスの複製の阻害剤 |
EP3294717B1 (en) | 2015-05-13 | 2020-07-29 | Vertex Pharmaceuticals Inc. | Methods of preparing inhibitors of influenza viruses replication |
US20180305350A1 (en) | 2015-06-24 | 2018-10-25 | Principia Biopharma Inc. | Tyrosine kinase inhibitors |
ES2794868T3 (es) * | 2015-06-30 | 2020-11-19 | Univ Texas | Inhibidores de GLS1 para el tratamiento de enfermedades |
EP3355926A4 (en) | 2015-09-30 | 2019-08-21 | Vertex Pharmaceuticals Inc. | METHOD FOR THE TREATMENT OF CANCER WITH A COMBINATION OF DNA DAMAGING AGENTS AND ATR INHIBITORS |
US20170100396A1 (en) | 2015-10-07 | 2017-04-13 | F. Hoffmann-La Roche Ag | Pyrrolopyrazine derivatives for use in the treatment, amelioration or prevention of influenza |
US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
SG10201913986YA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
CN108602782B (zh) | 2015-12-22 | 2022-06-17 | 德克萨斯大学系统董事会 | N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物 |
IL263815B (en) | 2016-06-29 | 2022-07-01 | Principia Biopharma Inc | Modified release formulations of 2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[4,3-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4 -Methyl-4-[4-(Oxtan-3-yl)piperazin-1-yl)pent-2-ananitrile |
WO2018177993A1 (de) | 2017-03-31 | 2018-10-04 | Bayer Cropscience Aktiengesellschaft | Pyrazole zur bekämpfung von arthropoden |
RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
JP7098212B2 (ja) * | 2017-12-04 | 2022-07-11 | エフ.ホフマン-ラ ロシュ アーゲー | B型肝炎ウイルス(HBV)感染の処置のためのcccDNA阻害剤としてのピロロ[2,3-b]ピラジン化合物 |
CA3086759A1 (en) * | 2018-01-05 | 2019-07-11 | Ac Immune Sa | 1,3,4,5-tetrahydro-2h-pyrido[4,3-b]indole derivatives for the treatment, alleviation or prevention of disorders associated with tau aggregates like alzheimer's disease |
CA3145813A1 (en) * | 2019-07-03 | 2021-01-07 | Borah, Inc. | Chemical compounds |
WO2021124155A1 (en) | 2019-12-20 | 2021-06-24 | Pfizer Inc. | Benzimidazole derivatives |
WO2023025109A1 (zh) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | 一类Toll样受体抑制剂及其制备和应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID26698A (id) * | 1998-06-19 | 2001-02-01 | Pfizer Prod Inc | SENYAWA-SENYAWA PIROLO [2,3-d] PIRIMIDINA |
CN1615873A (zh) * | 1999-12-24 | 2005-05-18 | 阿文蒂斯药物有限公司 | 氮杂吲哚类化合物 |
GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
WO2003082868A1 (en) * | 2002-03-28 | 2003-10-09 | Eisai Co., Ltd. | 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders |
US20070066641A1 (en) * | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
EP1696920B8 (en) | 2003-12-19 | 2015-05-06 | Plexxikon Inc. | Compounds and methods for development of ret modulators |
US7626021B2 (en) * | 2004-07-27 | 2009-12-01 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
CA2573573A1 (en) * | 2004-07-27 | 2006-02-09 | Sgx Pharmaceuticals, Inc. | Fused ring heterocycle kinase modulators |
WO2006058074A1 (en) * | 2004-11-22 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
US7456289B2 (en) | 2004-12-31 | 2008-11-25 | National Health Research Institutes | Anti-tumor compounds |
WO2007015866A2 (en) * | 2005-07-20 | 2007-02-08 | Kalypsys, Inc. | Inhibitors of p38 kinase and methods of treating inflammatory disorders |
CL2007002617A1 (es) | 2006-09-11 | 2008-05-16 | Sanofi Aventis | Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto. |
WO2008063888A2 (en) * | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
PE20081581A1 (es) * | 2006-12-21 | 2008-11-12 | Plexxikon Inc | COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA |
-
2009
- 2009-02-16 KR KR1020107018678A patent/KR101261514B1/ko not_active IP Right Cessation
- 2009-02-16 PT PT09713736T patent/PT2247592E/pt unknown
- 2009-02-16 MX MX2010008198A patent/MX2010008198A/es active IP Right Grant
- 2009-02-16 CN CN200980104705.5A patent/CN101939324B/zh not_active Expired - Fee Related
- 2009-02-16 JP JP2010548069A patent/JP5368485B2/ja not_active Expired - Fee Related
- 2009-02-16 RU RU2010139566/04A patent/RU2503676C2/ru not_active IP Right Cessation
- 2009-02-16 BR BRPI0908494-0A patent/BRPI0908494A2/pt not_active IP Right Cessation
- 2009-02-16 DK DK09713736.8T patent/DK2247592T3/da active
- 2009-02-16 PL PL09713736T patent/PL2247592T3/pl unknown
- 2009-02-16 AT AT09713736T patent/ATE522535T1/de active
- 2009-02-16 WO PCT/EP2009/051757 patent/WO2009106442A1/en active Application Filing
- 2009-02-16 EP EP09713736A patent/EP2247592B1/en not_active Not-in-force
- 2009-02-16 CA CA2713710A patent/CA2713710A1/en not_active Abandoned
- 2009-02-16 AU AU2009218607A patent/AU2009218607B2/en not_active Ceased
- 2009-02-20 US US12/378,978 patent/US7939531B2/en not_active Expired - Fee Related
- 2009-02-23 AR ARP090100621A patent/AR070468A1/es unknown
- 2009-02-23 TW TW098105681A patent/TWI380987B/zh not_active IP Right Cessation
- 2009-02-23 CL CL2009000406A patent/CL2009000406A1/es unknown
- 2009-02-23 PE PE2009000259A patent/PE20091493A1/es not_active Application Discontinuation
-
2010
- 2010-06-14 IL IL206358A patent/IL206358A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP5368485B2 (ja) | 2013-12-18 |
PE20091493A1 (es) | 2009-09-25 |
WO2009106442A1 (en) | 2009-09-03 |
BRPI0908494A2 (pt) | 2015-08-11 |
RU2503676C2 (ru) | 2014-01-10 |
TWI380987B (zh) | 2013-01-01 |
CN101939324B (zh) | 2014-10-15 |
AU2009218607A1 (en) | 2009-09-03 |
RU2010139566A (ru) | 2012-04-10 |
CL2009000406A1 (es) | 2010-09-21 |
CN101939324A (zh) | 2011-01-05 |
DK2247592T3 (da) | 2011-09-26 |
AR070468A1 (es) | 2010-04-07 |
AU2009218607B2 (en) | 2014-02-13 |
CA2713710A1 (en) | 2009-09-03 |
ATE522535T1 (de) | 2011-09-15 |
IL206358A0 (en) | 2010-12-30 |
JP2011513262A (ja) | 2011-04-28 |
EP2247592B1 (en) | 2011-08-31 |
KR101261514B1 (ko) | 2013-05-07 |
EP2247592A1 (en) | 2010-11-10 |
TW200938547A (en) | 2009-09-16 |
PL2247592T3 (pl) | 2012-01-31 |
KR20100114094A (ko) | 2010-10-22 |
US20090215750A1 (en) | 2009-08-27 |
PT2247592E (pt) | 2011-11-03 |
US7939531B2 (en) | 2011-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2010008198A (es) | Inhibidores de cinasa de pirrolopirazina. | |
PL2250172T3 (pl) | Pirolopirazynowe inhibitory kinazy | |
TW200942543A (en) | Pyrrolopyrazine kinase inhibitors | |
ATE517107T1 (de) | Pyrrolopyrazinkinaseinhibitoren | |
MX359032B (es) | Inhibidores de pirrolopirazina cinasa. | |
WO2011117145A3 (en) | Pyrrolopyrazine kinase inhibitors | |
ATE522534T1 (de) | Pyrrolopyrazin-kinasehemmer | |
MX342310B (es) | Compuestos de tiazolopirimidina. | |
MX343561B (es) | Compuestos de imidazolpiridazina. | |
MX2012002641A (es) | Inhibidores de cinasa janus (jak). | |
MX352928B (es) | Compuestos de piridazina-amida. | |
PT2470546E (pt) | Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor | |
JO3007B1 (ar) | مركبات و تركيبات كمثبطات كيناز بروتين | |
TW200626610A (en) | Analogs of 17-hydroxywortmannin as PI3K inhibitors | |
EP2170337A4 (en) | NEW TRIAZOLOPYRIDAZINE | |
MY150596A (en) | Hsp90 inhibitors | |
MX2012002385A (es) | Inhibidores macrociclicos de cinasa janus. | |
MX2013001970A (es) | Compuestos de pirrolopirimidina y usos de los mismos. | |
MY150542A (en) | Cmet inhibitors | |
HK1135103A1 (en) | Dihydropyridine derivatives useful as protein kinase inhibitors | |
EA201170521A1 (ru) | Новые соединения | |
UA109775C2 (xx) | N-вмісні гетероарильні похідні як інгібітори jak3-кінази | |
JO2998B1 (ar) | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان | |
WO2010008847A3 (en) | Pi3k/m tor inhibitors | |
UA108743C2 (uk) | Похідні хіназолін-4(3н)-ону для застосування як інгібіторів рі3-кінази |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |